circulating tumor DNA (ctDNA)

DIAGNOSTIC_TEST2 trials

Sponsors

Turku University Hospital, Julia Foldi

Conditions

High Grade Ovarian Serous AdenocarcinomaHigh Grade Serous CarcinomaMetastatic Invasive Lobular Carcinoma (mILC)

Unknown Phase

Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC

RecruitingNCT04846933

Turku University HospitalHigh Grade Ovarian Serous Adenocarcinoma, High Grade Serous Carcinoma

Start: 2012-02-01End: 2029-12-31Target: 200Updated: 2025-01-16

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

RecruitingNCT06666439

Julia FoldiMetastatic Invasive Lobular Carcinoma (mILC)

Start: 2024-12-12End: 2029-10-31Target: 20Updated: 2026-01-20

Related Papers

Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer.

2025-08-291 citations

Abstract 1257: Response to primary therapy predicts tumor evolution dynamics at relapse in ovarian cancer

Cancer Research2025-04-21

Abstract PR003: DNA methylation reveals metastatic colonization routes in ovarian cancer

Cancer Research2025-02-01

Abstract 4249: Establishment and analysis of patient-derived high-grade serous ovarian cancer organoids for disease modeling and drug testing

Cancer Research2024-03-22

Abstract 4940: Unraveling ctDNA features in high-grade serous ovarian carcinoma and insights from genomic and transcriptomic integration

Cancer Research2024-03-22

Abstract 7014: Integrative DNA methylation cancer profiling reveals patterns associated with tumor progression and treatment response

Cancer Research2024-03-22

Abstract 1617: Tumor evolution during therapy in ovarian cancer

Cancer Research2024-03-22

Abstract B102: Mutational and copy number-based ctDNA profiles mirror high-grade serous cancer tumors and enable detection of genetic changes appearing at recurrence

Cancer Research2024-03-041 citations

Abstract A003: Characterizing DNA methylation patterns driving chemotherapy resistance in ovarian high-grade serous carcinoma

Cancer Research2024-03-04

Abstract A027: Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma

Cancer Research2024-03-04

Abstract B027: Screening of drug candidates to repurpose for high-grade serous ovarian cancer treatment

Cancer Research2024-03-04